Clinical manifestation and laboratory features in MDS patients with and without SRSF2 mutation
| Variable . | SRSF2 mutation (−) (n = 199, 85.4%) . | SRSF2 mutation (+) (n = 34, 14.6%) . | Total (n = 233) . | P . |
|---|---|---|---|---|
| Sex* | .001 | |||
| Male | 129 (80.1) | 32 (19.9) | 161 | |
| Female | 70 (97.2) | 2 (2.8) | 72 | |
| Age, y† | 63.0 (18-91) | 74.5 (49-95) | 66.0 | < .001 |
| > 50* | 151 (82.1) | 33 (17.9) | 184 | .005 |
| ≦ 50* | 48 (98.0) | 1 (2.0) | 49 | |
| Lab data† | ||||
| WBC, /μL | 4205 (440-3 55300) | 4705 (1 250-38 180) | 4215 | .649 |
| Hb, g/dL | 8.3 (3.4-14.4) | 8.45 (4.0-14.6) | 8.4 | .236 |
| Platelet, × 1000/μL | 83.0 (2.0-607.0) | 86.0 (7.0-535.0) | 83.0 | .929 |
| LDH, U/L | 491.5 (145-6807) | 526.5 (230-1261) | 501.5 | .721 |
| FAB subtype* | .025 | |||
| RA/RARS | 88 (89.8) | 10 (10.2) | 98 | |
| RAEB/RAEBT | 88 (86.3) | 14 (13.7) | 102 | |
| CMML | 23 (69.7) | 10 (30.3) | 33 | |
| WHO subtype (n = 171)*‡ | .766 | |||
| RA/RCMD/RCUD§ | 87 (89.7) | 10 (10.3) | 97 | |
| RAEB1 | 31 (86.1) | 5 (13.9) | 36 | |
| RAEB2 | 33 (86.8) | 5 (13.2) | 38 | |
| Karyotype risk (n = 214)‖ | .128 | |||
| Good | 100 (84.0) | 19 (16.0) | 119 | |
| Intermediate | 38 (79.2) | 10 (20.8) | 48 | |
| Poor | 44 (93.6) | 3 (6.4) | 47 | |
| IPSS (n = 214)¶ | .995 | |||
| Low | 26 (86.7) | 4 (13.3) | 30 | |
| INT-1 | 72 (84.7) | 13 (15.3) | 85 | |
| INT-2 | 50 (84.7) | 9 (15.3) | 59 | |
| High | 34 (85.0) | 6 (15.0) | 40 |
| Variable . | SRSF2 mutation (−) (n = 199, 85.4%) . | SRSF2 mutation (+) (n = 34, 14.6%) . | Total (n = 233) . | P . |
|---|---|---|---|---|
| Sex* | .001 | |||
| Male | 129 (80.1) | 32 (19.9) | 161 | |
| Female | 70 (97.2) | 2 (2.8) | 72 | |
| Age, y† | 63.0 (18-91) | 74.5 (49-95) | 66.0 | < .001 |
| > 50* | 151 (82.1) | 33 (17.9) | 184 | .005 |
| ≦ 50* | 48 (98.0) | 1 (2.0) | 49 | |
| Lab data† | ||||
| WBC, /μL | 4205 (440-3 55300) | 4705 (1 250-38 180) | 4215 | .649 |
| Hb, g/dL | 8.3 (3.4-14.4) | 8.45 (4.0-14.6) | 8.4 | .236 |
| Platelet, × 1000/μL | 83.0 (2.0-607.0) | 86.0 (7.0-535.0) | 83.0 | .929 |
| LDH, U/L | 491.5 (145-6807) | 526.5 (230-1261) | 501.5 | .721 |
| FAB subtype* | .025 | |||
| RA/RARS | 88 (89.8) | 10 (10.2) | 98 | |
| RAEB/RAEBT | 88 (86.3) | 14 (13.7) | 102 | |
| CMML | 23 (69.7) | 10 (30.3) | 33 | |
| WHO subtype (n = 171)*‡ | .766 | |||
| RA/RCMD/RCUD§ | 87 (89.7) | 10 (10.3) | 97 | |
| RAEB1 | 31 (86.1) | 5 (13.9) | 36 | |
| RAEB2 | 33 (86.8) | 5 (13.2) | 38 | |
| Karyotype risk (n = 214)‖ | .128 | |||
| Good | 100 (84.0) | 19 (16.0) | 119 | |
| Intermediate | 38 (79.2) | 10 (20.8) | 48 | |
| Poor | 44 (93.6) | 3 (6.4) | 47 | |
| IPSS (n = 214)¶ | .995 | |||
| Low | 26 (86.7) | 4 (13.3) | 30 | |
| INT-1 | 72 (84.7) | 13 (15.3) | 85 | |
| INT-2 | 50 (84.7) | 9 (15.3) | 59 | |
| High | 34 (85.0) | 6 (15.0) | 40 |
WBC indicates white blood cells; Hb, hemoglobin; LDH, lactate dehydrogenase; RAEBT, refractory anemia with excess blasts in transformation; RCUD, refractory cytopenia with unilineage dysplasia; and RCMD, refractory cytopenia with multilineage dysplasia.
Number of patients (%).
Median (range).
One patient with MDS, unclassifiable, by WHO classification was excluded from the statistical analysis.
With or without ring sideroblasts.
Good, normal karyotype, isolated -Y, del(5q) or del(20q); poor, complex (≥ 3 abnormalities) or chromosome 7 anomalies; and intermediate, other abnormalities.
International prognosis scoring system: low, 0; intermediate (INT)–1, 0.5-1; INT-2, 1.5-2; and high, ≥ 2.5.